Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?

Executive Summary

Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.

You may also be interested in...



Exec Chat: MeMed Improves Diagnostics To Combat Antimicrobial resistance

Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.

Real-World Evidence Deemed Essential For Breakthrough Designations

A panel of experts in the health care and medical device industries discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference.

Start-Up Spotlight: Manus Neurodynamica Hopes To Write The End Of Traditional Parkinson’s Diagnosis

Manus Neurodynamica intends to launch a pen, which provides early and accurate diagnosis of Parkinson’s disease, to the UK and Benelux markets and has £5m in funding to date.

Topics

UsernamePublicRestriction

Register

MT144925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel